PWAM
PCVX icon

Private Wealth Asset Management’s Vaxcyte PCVX Stock Holding History

Private Wealth Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$92 – 1086
2025
Q4 		$92 Hold
2
– – ﹤0.01% 1088
2025
Q3 		$72 Hold
2
– – ﹤0.01% 1087
2025
Q2 		$65 Hold
2
– – ﹤0.01% 1080
2025
Q1 		$76 Buy
+2
New +$160 ﹤0.01% 1173

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Private Wealth Asset Management's PCVX Position: Q1 2026 in Review

Private Wealth Asset Management sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 2 shares — an estimated $92 sold.

Private Wealth Asset Management first reported a position in PCVX in Q1 2025 and held it in 4 quarters. The position peaked at $92 in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Private Wealth Asset Management reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Private Wealth Asset Management sold 2 Vaxcyte shares in Q1 2026, an estimated $92.
  • Private Wealth Asset Management first reported a position in Vaxcyte in Q1 2025 and held it in 4 quarters.
  • Private Wealth Asset Management's Vaxcyte position peaked at $92 in Q4 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Private Wealth Asset Management's 13F filing for Q1 2026, filed 6 May 2026.